Second, as mentioned above, the glucose-lowering strategies used in the ACCORD study (primarily sulfonylureas and insulin) differed from current strategies for managing blood glucose in patients with type 2 diabetes, which increasingly utilize SGLT2 inhibitors and GLP-1 receptor agonists. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.